Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper

• Published in: Drug metabolism and disposition Vol. 44; no. 5; pp. 617 - 623
• Main Authors: Kraynov, Eugenia, Kamath, Amrita V., Walles, Markus, Tarcsa, Edit, Deslandes, Antoine, Iyer, Ramaswamy A., Datta-Mannan, Amita, Sriraman, Priya, Bairlein, Michaela, Yang, Johnny J., Barfield, Matthew, Xiao, Guangqing, Escandon, Enrique, Wang, Weirong, Rock, Dan A., Chemuturi, Nagendra V., Moore, David J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2016
• Subjects: Animals; Antibodies, Monoclonal - metabolism; Drug Industry - methods; Humans; Immunoconjugates - metabolism; Pharmaceutical Preparations - metabolism; ADC; MMAE; DAR; Tab; ADME; DDI; DM; P450; PK; ADA; mAb
• ISSN: 0090-9556; 1521-009X; 1521-009X
• DOI: 10.1124/dmd.115.068049

An antibody-drug conjugate (ADC) is a unique therapeutic modality composed of a highly potent drug molecule conjugated to a monoclonal antibody. As the number of ADCs in various stages of nonclinical and clinical development has been increasing, pharmaceutical companies have been exploring diverse approaches to understanding the disposition of ADCs. To identify the key absorption, distribution, metabolism, and excretion (ADME) issues worth examining when developing an ADC and to find optimal scientifically based approaches to evaluate ADC ADME, the International Consortium for Innovation and Quality in Pharmaceutical Development launched an ADC ADME working group in early 2014. This white paper contains observations from the working group and provides an initial framework on issues and approaches to consider when evaluating the ADME of ADCs.